- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2190-9172
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Cost–Utility Analysis of Nivolumab in Adjuvant Treatment of Melanoma in France ; day:13 ; month:9 ; year:2020 ; pages:1-13
Dermatology and therapy ; (13.9.2020), 1-13
- Creator
-
Bregman, Bruno
Teitsson, Siguroli
Orsini, Isabella
Cotté, François-Emery
Amadi, Adenike
Moshyk, Andriy
Roze, Stéphane
Gaudin, Anne-Françoise
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s13555-020-00446-z
- URN
-
urn:nbn:de:101:1-2020110121165516079186
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:34 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Bregman, Bruno
- Teitsson, Siguroli
- Orsini, Isabella
- Cotté, François-Emery
- Amadi, Adenike
- Moshyk, Andriy
- Roze, Stéphane
- Gaudin, Anne-Françoise
- SpringerLink (Online service)
Other Objects (12)
Cost-utility analysis of adjuvant goserelin (Zoladex) and adjuvant chemotherapy in premenopausal women with breast cancer
Autoimmune radiculoplexus neuropathy under adjuvant nivolumab treatment of a female patient with melanoma
Comparison of EQ-5D-3L with QLU-C10D in Metastatic Melanoma Using Cost-Utility Analysis
Cost-utility analysis of adjuvant trastuzumab therapy for HER2-positive early-stage breast cancer in the Philippines
Nivolumab adjuvant, Nivolumab plus Ipilimumab : Meilensteine in der Behandlung des malignen Melanoms
Cost-Utility of Nivolumab Plus Ipilimumab in First-Line Treatment of Advanced Melanoma in the United States: An Analysis Using Long-Term Overall Survival Data from Checkmate 067
Nivolumab plus Ipilimumab, Nivolumab adjuvant : Diskussion zur Therapieentscheidung bei BRAF-mutierten Melanom Patienten
Nivolumab (Melanom, adjuvant) : Addendum zum Auftrag A21-39
Neoadjuvant relatlimab and nivolumab in resectable melanoma
Cost-utility of tiotropium in patients with severe asthma
Cost-utility analysis of an implant treatment in dentistry
Nivolumab adjuvant, Nivolumab plus Ipilimumab : Meilensteine in der Behandlung des malignen Melanoms : Update 2021
Cost-utility analysis of adjuvant goserelin (Zoladex) and adjuvant chemotherapy in premenopausal women with breast cancer
Autoimmune radiculoplexus neuropathy under adjuvant nivolumab treatment of a female patient with melanoma
Comparison of EQ-5D-3L with QLU-C10D in Metastatic Melanoma Using Cost-Utility Analysis
Cost-utility analysis of adjuvant trastuzumab therapy for HER2-positive early-stage breast cancer in the Philippines
Nivolumab adjuvant, Nivolumab plus Ipilimumab : Meilensteine in der Behandlung des malignen Melanoms
Cost-Utility of Nivolumab Plus Ipilimumab in First-Line Treatment of Advanced Melanoma in the United States: An Analysis Using Long-Term Overall Survival Data from Checkmate 067
Nivolumab plus Ipilimumab, Nivolumab adjuvant : Diskussion zur Therapieentscheidung bei BRAF-mutierten Melanom Patienten
Nivolumab (Melanom, adjuvant) : Addendum zum Auftrag A21-39
Neoadjuvant relatlimab and nivolumab in resectable melanoma
Cost-utility of tiotropium in patients with severe asthma
Cost-utility analysis of an implant treatment in dentistry
Nivolumab adjuvant, Nivolumab plus Ipilimumab : Meilensteine in der Behandlung des malignen Melanoms : Update 2021
Cost-utility analysis of adjuvant goserelin (Zoladex) and adjuvant chemotherapy in premenopausal women with breast cancer
Autoimmune radiculoplexus neuropathy under adjuvant nivolumab treatment of a female patient with melanoma
Comparison of EQ-5D-3L with QLU-C10D in Metastatic Melanoma Using Cost-Utility Analysis
Cost-utility analysis of adjuvant trastuzumab therapy for HER2-positive early-stage breast cancer in the Philippines
Nivolumab adjuvant, Nivolumab plus Ipilimumab : Meilensteine in der Behandlung des malignen Melanoms
Cost-Utility of Nivolumab Plus Ipilimumab in First-Line Treatment of Advanced Melanoma in the United States: An Analysis Using Long-Term Overall Survival Data from Checkmate 067
Nivolumab plus Ipilimumab, Nivolumab adjuvant : Diskussion zur Therapieentscheidung bei BRAF-mutierten Melanom Patienten
Nivolumab (Melanom, adjuvant) : Addendum zum Auftrag A21-39
Neoadjuvant relatlimab and nivolumab in resectable melanoma
Cost-utility of tiotropium in patients with severe asthma
Cost-utility analysis of an implant treatment in dentistry